Biosimulation software, technology and services to transform traditional drug discovery and development.

Certara leverages advanced technologies to enhance drug development processes through Model Informed Drug Development (MIDD) solutions. Their software suite includes tools like the Phoenix™ Pharmacokinetic/Pharmacodynamic Platform, which is recognized as a leader in preparing clinical trial data for regulatory submissions. Additionally, the Simcyp™ Physiologically Based Pharmacokinetic (PBPK) modeling platform allows for the prediction of drug behavior in various physiological compartments, facilitating informed decision-making in drug development. Certara's D360™ Scientific Informatics Platform and Pinnacle 21 Enterprise Software further streamline data management and compliance, enabling researchers to efficiently analyze and visualize data, thereby accelerating the overall drug development timeline.

Incorporating artificial intelligence, Certara's CoAuthor™ platform revolutionizes regulatory writing by enhancing collaboration and efficiency among writing teams. Their SEND Explorer® application provides advanced visualization and summarization capabilities for nonclinical study data, ensuring that scientists can easily access and interpret critical information. By integrating these technologies, Certara not only improves the quality and speed of regulatory submissions but also supports pharmaceutical and biotechnology companies in making data-driven decisions throughout the drug development lifecycle. This comprehensive approach positions Certara as a trusted partner in navigating the complexities of drug development and regulatory compliance.

France

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include 2,000 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries.

Certara

Company Details